Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary Embolism

This study is a prospective, single-arm, non-randomized, interventional, multicenter feasibility study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).

Study Overview

• Status: Recruiting
• Conditions: Pulmonary Embolism Acute
• Intervention / Treatment: Device: ATC System

• Study Type: Interventional
• Enrollment (Estimated): 15
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Uday Illindala; Phone Number: 4085602500; Email: clinicalaffairs@akuramed.com
• Study Contact Backup: Name: Rukhsana Khanum; Phone Number: 4085602500; Email: clinicalaffairs@akuramed.com

Study Locations

• Austria
  • Graz, Austria
    • Recruiting
    • Univ.-Klinikum LKH Graz
    • Contact: Claudia Wöhrer,; Email: claudia.woehrer@medunigraz.at

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient is > 18 and < 90 years old
2. Clinical signs and symptoms consistent with acute PE
3. PE symptom duration ≤ 14 days
4. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery as determined by the investigator)
5. CTA evidence of RV/LV ratio > 0.9 note: based on Investigator's interpretation of RV/LV ratio at baseline;
6. Systolic BP ≥ 90 mmHg note: initial SBP may be < 90 mmHg but ≥ 80 mmHg if the pressure recovers with volume resuscitation
7. Stable heart rate (HR) < 130 BPM prior to procedure
8. Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment.
9. Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures

Exclusion Criteria:

1. Prior PE < 180 days from index procedure
2. Thrombolytic use < 48 hours prior to baseline CTA
3. Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) >70 mmHg by right heart catheterization
4. Vasopressor requirement after fluids to keep pressure at ≥90 mmHg
5. FiO2 requirement >40% or >6 LPM to keep oxygen saturation >90%
6. Hematocrit <28% (Note: hematocrit required within 6 hrs. of index procedure)
7. Platelets count <100,000/µL
8. eGFR <30 ml/min per 1.73 m2
9. International normalized ratio (INR) >3
10. Major trauma injury severity score (ISS) > 15
11. Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment
12. Cardiovascular or pulmonary surgery within 7 days of index procedure
13. Actively progressing cancer treated by chemotherapeutics
14. Known bleeding diathesis or coagulation disorder
15. Left bundle branch block
16. History of severe or chronic pulmonary arterial hypertension
17. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
18. History of decompensated heart failure
19. History of underlying lung disease that is oxygen dependent
20. History of chest irradiation
21. History of heparin-induced thrombocytopenia (HIT)
22. Contraindication to systemic or therapeutic doses of anticoagulants
23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
24. Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and/or right ventricle).
25. CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
26. Life expectancy <90 days, as determined by investigator
27. Female who is pregnant or nursing
28. Current participation in another investigational drug or device treatment study Note: observational or registry studies may be permitted with Sponsor approval

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patients with Acute Pulmonary Embolism; Patients undergoing mechanical thrombectomy for acute pulmonary embolism.	Device: ATC System; The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety: Composite of Major Adverse Device-Related Events	Device-related major bleeding at access, device-related death, clinical deterioration, pulmonary vascular injury or cardiac injury	48 hours post index procedure
Effectiveness	Change in RV/LV ratio post index procedure	48 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety: Composite of Major Adverse Events	Assessment of major adverse events through 30 day follow-up	30 days post index procedure

Collaborators and Investigators

• Sponsor: Akura Medical

Study record dates

Study Major Dates

• Study Start (Actual): February 15, 2025
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): February 1, 2026

Study Registration Dates

• First Submitted: April 9, 2024
• First Submitted That Met QC Criteria: April 9, 2024
• First Posted (Actual): April 12, 2024

Study Record Updates

• Last Update Posted (Actual): July 28, 2025
• Last Update Submitted That Met QC Criteria: July 24, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Respiratory Tract Diseases; Lung Diseases; Embolism and Thrombosis; Pulmonary Embolism; Embolism
• Other Study ID Numbers: CP-60005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes